Covid vaccines may be less effective against Omicron variant: WHO

The WHO, in its weekly epidemiological update, said that more data was needed to better understand the extent to which Omicron may evade immunity derived from either vaccines or previous infection

A health worker takes a swab at a Covid-19 testing site in Uttar Pradesh, on May 4.(Photo: Bloomberg)
A health worker takes a swab at a Covid-19 testing site in Uttar Pradesh. (File photo: Bloomberg)
Reuters
2 min read Last Updated : Dec 15 2021 | 7:49 PM IST
Preliminary evidence indicates that COVID-19 vaccines may be less effective against infection and transmission linked to the Omicron coronavirus variant, which also carries a higher risk of reinfection, the World Health Organization said on Wednesday.

The WHO, in its weekly epidemiological update, said that more data was needed to better understand the extent to which Omicron may evade immunity derived from either vaccines or previous infection.

"As a result of this, the overall risk related to the new variant of concern Omicron remains very high," it said, echoing comments made by WHO officials at an online briefing on Tuesday.

For the first time since the dominant Delta variant was classified as a variant of concern in April, the percentage of Delta sequences registered on the GISAID global science database has declined this week compared with other variants of concern, it said.

This needs to be interpreted with caution as countries may perform targeted sequencing for Omicron and therefore upload fewer sequences on all other variants, including Delta, it said.

The Delta variant is still dominant, however, accounting for 99.2% of the almost 880,000 sequences uploaded to GISAID with specimens collected in the last 60 days.

But the trend is declining in the proportion of Alpha, Beta and Gamma, and with the emergence of Omicron variant. Out of the total, some 3,755 - or 0.4% - were Omicron and the other three variants of concern together numbered 401, less than 0.1% each.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineWorld Health Organization

Next Story